Matthew Hamilton Rosenberg’s CRISPR Therapeutics CRSP Stock Holding History

Matthew Hamilton Rosenberg’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-80	Closed	-$3.25K	–	939
2022 Q4	$3.25K	Hold	80	–	–	﹤0.01%	750
2022 Q3	$5K	Hold	80	–	–	﹤0.01%	707
2022 Q2	$5K	Hold	80	–	–	﹤0.01%	693
2022 Q1	$5K	Hold	80	–	–	﹤0.01%	674
2021 Q4	$6K	Hold	80	–	–	﹤0.01%	634
2021 Q3	$9K	Hold	80	–	–	﹤0.01%	582
2021 Q2	$13K	Hold	80	–	–	0.01%	492
2021 Q1	$10K	Buy	+80	New	+$12.1K	0.01%	493

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Matthew Hamilton Rosenberg's CRSP Position: Q1 2023 in Review

Matthew Hamilton Rosenberg sold out of CRISPR Therapeutics (CRSP) in Q1 2023, closing a stake of 80 shares — an estimated $3.25K sold.

Matthew Hamilton Rosenberg first reported a position in CRSP in Q1 2021 and held it in 8 quarters. The position peaked at $13K in Q2 2021. 381 funds tracked by Wall St. Rank hold CRSP as of Q1 2023.

Matthew Hamilton Rosenberg reported no remaining CRISPR Therapeutics position as of Q1 2023 after selling out during the quarter.
Matthew Hamilton Rosenberg sold 80 CRISPR Therapeutics shares in Q1 2023, an estimated $3.25K.
Matthew Hamilton Rosenberg first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 8 quarters.
Matthew Hamilton Rosenberg's CRISPR Therapeutics position peaked at $13K in Q2 2021.
381 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2023.

Based on Matthew Hamilton Rosenberg's 13F filing for Q1 2023, filed 17 Apr 2023.